Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Synthetic oxepanoprolinamide iboxamycin is active against Listeria monocytogenes despite the intrinsic resistance mediated by VgaL/Lmo0919 ABCF ATPase

Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

DOI

  1. Structural basis for PoxtA-mediated resistance to phenicol and oxazolidinone antibiotics

    Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

  2. A hyperpromiscuous antitoxin protein domain for the neutralization of diverse toxin domains

    Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

  3. RelA-SpoT Homolog toxins pyrophosphorylate the CCA end of tRNA to inhibit protein synthesis

    Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

  • Tetiana Brodiazhenko
  • Kathryn Jane Turnbull
  • Kelvin J Y Wu
  • Hiraku Takada
  • Ben I C Tresco
  • Tanel Tenson
  • Andrew G Myers
  • Vasili Hauryliuk
Vis graf over relationer

Background: Listeriosis is a food-borne disease caused by the Gram-positive Bacillota (Firmicute) bacterium Listeria monocytogenes. Clinical L. monocytogenes isolates are often resistant to clinically used lincosamide clindamycin, thus excluding clindamycin as a viable treatment option.

Objectives: We have established newly developed lincosamide iboxamycin as a potential novel antilisterial agent.

Methods: We determined MICs of the lincosamides lincomycin, clindamycin and iboxamycin for L. monocytogenes, Enterococcus faecalis and Bacillus subtilis strains expressing synergetic antibiotic resistance determinants: ABCF ATPases that directly displace antibiotics from the ribosome and Cfr, a 23S rRNA methyltransferase that compromises antibiotic binding. For L. monocytogenes strains, either expressing VgaL/Lmo0919 or lacking the resistance factor, we performed time-kill kinetics and post-antibiotic effect assays.

Results: We show that the synthetic lincosamide iboxamycin is highly active against L. monocytogenes and can overcome the intrinsic lincosamide resistance mediated by VgaL/Lmo0919 ABCF ATPase. While iboxamycin is not bactericidal against L. monocytogenes, it displays a pronounced post-antibiotic effect, which is a valuable pharmacokinetic feature. We demonstrate that VmlR ABCF of B. subtilis grants significant (33-fold increase in MIC) protection from iboxamycin, while LsaA ABCF of E. faecalis grants an 8-fold protective effect. Furthermore, the VmlR-mediated iboxamycin resistance is cooperative with that mediated by the Cfr, resulting in up to a 512-fold increase in MIC.

Conclusions: While iboxamycin is a promising new antilisterial agent, our findings suggest that emergence and spread of ABCF ARE variants capable of defeating next-generation lincosamides in the clinic is possible and should be closely monitored.

OriginalsprogEngelsk
Artikelnummerdlac061
TidsskriftJAC-antimicrobial resistance
Vol/bind4
Udgave nummer3
Sider (fra-til)dlac061
ISSN2632-1823
DOI
StatusUdgivet - jun. 2022

Bibliografisk note

© The Author(s) 2022. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy.

ID: 79087675